Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33.CAR NK TGFβi
- Development stage
- Preclinical
- Lead developer
- Nationwide Children's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD33.CAR NK TGFβi is an experimental cell therapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD33, a surface antigen highly expressed in acute myeloid leukemia (AML) blasts. These cells undergo "TGFβ imprinting" (TGFβi) during expansion, a process involving chronic TGFβ stimulation that induces high levels of IFNγ and TNF secretion and confers resistance to TGFβ-mediated immunosuppression within the tumor microenvironment. Developed by researchers at New York Medical College and Nationwide Children's Hospital, this therapy is designed to overcome the limitations of conventional NK cell persistence and potency. Preclinical studies demonstrate that the combination of CD33 targeting and TGFβ imprinting, particularly when augmented by IL-15 receptor agonists like NKTR-255, significantly enhances cytotoxicity and survival in AML models.
- Other names
- TGFβ-imprinted CD33-directed CAR-NK cellsCD33.CAR NK cells with TGFβ imprinting
02
Targets
CD33 (Myeloid cell surface antigen CD33)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on CD33.CAR NK TGFβi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33.CAR NK TGFβi.